Descovy Approval History
- FDA approved: Yes (First approved April 4th, 2016)
- Brand name: Descovy
- Generic name: emtricitabine and tenofovir alafenamide
- Dosage form: Tablets
- Company: Gilead Sciences, Inc.
- Treatment for: HIV Infection
Descovy (emtricitabine and tenofovir alafenamide) is a nucleoside analog HIV-1 reverse transcriptase inhibitor (NRTI) and nucleotide reverse transcriptase inhibitor (NtRTI) fixed-dose combination for the treatment of HIV-1 infection.
FDA approval of Descovy was supported by data from clinical studies which demonstrated that a tenofovir alafenamide (TAF) based regimen was as effective as a tenofovir disoproxil fumarate (TDF) based regimen in reducing viral loads, but with with less kidney toxicity and bone loss. Descovy is intended to be a safer replacement for Truvada (emtricitabine/tenofovir disoproxil fumarate (TDF), but unlike Truvada, Descovy is not approved for pre-exposure prophylaxis (PrEP).
The recommended dosage for Descovy is one tablet taken once daily with or without food. The most common side effect is nausea.
Development History and FDA Approval Process for Descovy
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.